Disease Markers / 2017 / Article / Tab 1 / Research Article
Are Fusion Transcripts in Relapsed/Metastatic Head and Neck Cancer Patients Predictive of Response to Anti-EGFR Therapies? Table 1 Presence and main characteristics of gene fusions detected in each RM-HNSCC patient of our selected case material; see [
10 ] for clinical pathologic characteristics of the patients.
Sample ID Gene fusion “Left” partner “Right” partner Gene Chromosome Gene Chromosome Short PFS under chemotherapy-cetuximab treatment GU05 No GU09 No GU10 Yes DLG2 Chr11 PICALM Chr11 NUMA1 Chr11 GRIA3 ChrX ZMYM2 Chr13 TRIM28 Chr19 GU11 No GU13 Yes CLTC Chr17 RPS6KB1 Chr17 GU14 Yes CD274 Chr9 PDCD1LG2 Chr9 GU15 No GU17 No GU18 No GU20 Yes CD274 Chr9 PDCD1LG2 Chr9 GU21 No GU22 No GU23 No GU24 Yes BMS1P20 Chr22 IGLL5 Chr22 GU25 Yes CD274 Chr9 PDCD1LG2 Chr9 GU26 Yes FGF12 Chr3 MB21D2 Chr3 GU27 No GU28 Yes METTL13 Chr1 DNM3 Chr1 CTNNA2 Chr2 HES1 Chr3 RPS6KA2 Chr6 RNASET2 Chr6 MUSK Chr9 LPAR1 Chr9 CD274 Chr9 PDCD1LG2 Chr9 TRAF3 Chr14 ENSG00000259717 Chr14 GU29 Yes CD274 Chr9 PDCD1LG2 Chr9 GU30 Yes RCSD1 Chr1 MPZL1 Chr1 GU31 Yes CD274 Chr9 PDCD1LG2 Chr9 PPP6R3 Chr11 MLL Chr11 GU34 Yes NUMA1 Chr11 GRIA3 ChrX ZMYM2 Chr13 TRIM28 Chr19 GU38 No GU40 No GU41 Yes PVT1 Chr8 ENSG00000253288 Chr8 GU43 Yes CD274 Chr9 PDCD1LG2 Chr9 Long PFS under chemotherapy cetuximab treatment GU04 Yes FLNB Chr3 ENSG00000245384 Chr4 GU06 No GU07 Yes METTL13 Chr1 DNM3 Chr1 MUSK Chr9 LPAR1 Chr9 ENSG00000231669 ChrX MSN ChrX GU08 Yes ENSG00000231669 ChrX MSN ChrX GU12 Yes C9 Chr5 RCOR1 Chr14 ENSG00000259446 Chr15 RYR3 Chr15 IGLV1-40 Chr22 IGLL5 Chr22 GU16 Yes WDR90 Chr16 RHOT2 Chr16 GU19 Yes ANK1 Chr8 KAT6A Chr8 ZBTB7A Chr19 MAP2K2 Chr19 GU32 Yes ZBTB7A Chr19 MAP2K2 Chr19 TPTE Chr21 BAGE2 Chr21 ENSG00000231669 ChrX MSN ChrX GU33 Yes ENSG00000231121 Chr12 NAV3 Chr12 GU35 No GU36 Yes ZC3H15 Chr2 ITGAV Chr2 PPP6R3 Chr11 MLL Chr11 ENSG00000231121 Chr12 NAV3 Chr12 PI4KA Chr22 CRKL Chr22 GU37 Yes ENSG00000231121 Chr12 NAV3 Chr12 GU39 No GU42 No
